New evidence from clinical trials shows that monoclonal antibodies against IL-17 can effectively treat inflammatory skin diseases such as psoriasis, suppurative hidrosis, atopic dermatitis, and pityriasis rubra [24, 25]. Here, IL17A is linked to inflammatory skin disease.